Core Viewpoint - The company, Heptares Therapeutics, has entered into a global strategic collaboration and licensing agreement with Bristol-Myers Squibb to discover and develop next-generation bispecific antibodies, which has positively impacted its stock price and trading volume [1]. Group 1: Financial Aspects - Heptares Therapeutics will receive an upfront payment of $90 million as part of the agreement [1]. - The company is eligible for up to $1.035 billion in development and commercial milestone payments, along with tiered royalties, if Bristol-Myers Squibb advances all potential projects [1]. Group 2: Recent Collaborations - Since 2025, Heptares Therapeutics has secured three major contracts with multinational corporations (MNCs), including a significant partnership with AstraZeneca worth 4.575 billion yuan, which involves multiple targets and projects [1]. - In June, the company established a global strategic collaboration with Otsuka Pharmaceutical regarding the BCMAxCD3 bispecific T-cell engager (HBM7020) [1]. - Overall, Heptares Therapeutics has completed seven collaborations with MNCs, with total external cooperation amounts exceeding $10 billion [1].
和铂医药-B早盘涨超8% 公司与百时美施贵宝签订超10亿美元BD交易